Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2017) 49 EP603 | DOI: 10.1530/endoabs.49.EP603

Hospital Rio Hortega, Valladolid, Spain.

In the late years ISGLT2 have became an usual choice to treat diabetes. The inhibition of the sodium-glucose co transporters (SLGT2) inhibits also the glucose reabsorption in the proximale tubule and increases the glucose excreted in the urine. Therefore hyperglycemia decreases and so does weight. This is a very convenient side effect since type 2 DM is highly associated with overweight/obesity. We show the results of HbA1c and weight evolution after starting canaglifozina 100 (added to the previous treatment) in 60 patients. Six of them (four women) had to stop the drug (three because of genital pruritus, one deterioration of renal function and one non related metastatic cancer). We also show the results of canaglifozina 300 in 17 patients. Women represented the 33% and the medium age was 62±7years. We show data after 6 and 12 months on canaglifozina100. We have studied separately people older than 65 years old: 15 patients with medium age of 71±4 years, 10 of them women. This group showed no side effects and no treatment interrumptions. In 30 people we studied uric acid levels, showing a difference of -0.9 mf/dl after 6 months on canaglifozina. Seventeen patients progress to canaglifozina 300, the medium age was 63.2 (±5,6) years. After 6 months they got an additional weight loss of 1.8 kg (±0.5) and decrease on HbA1c of −0.3% (±0.1). There were 18 patients on insuline therapy with an average of 32(±26) daily units one year later the average was 21 (±30) daily units of insulin. 2 patients stopped insulin therapy. Three patients stopped sunfonilurea previously to canaglifoniza 100. Initially HbA1c increased 0.3% (±0.1) and weight decreased 3.3 (±1.7) kg, patients referred decrease or disappearance of hypoglycemia. After one year on canaglifozina HbA1c decreased 0.2 (±0.1)% and weight decreased 4.8 (±2.2) kg. The 96% were satisfied with the new treatment for cana 100 and 100% for cana 300 (Table 1).

Conclusions: Canaglifozina 100 added to the previous treatment for DM2 improved glycaemic control and produced weight loss. Canaglifozina 300 improved even more this results. A decrease in uric acid levels was showed. The results were the same in the elderly group without increase of side effects. Patients on insulin decrease the dose with an improvement in the glycemic control. Stopping sulfonylurea produced a transient increase in glycaemia with less hypoglycemia. The mail side effect was non complicated urinary infection.

Table 1
A1cA1c6 monthsA1c 1 yearWeightWeight 6 monthsWeight 1 yearUricUric 1 year

Volume 49

19th European Congress of Endocrinology

Lisbon, Portugal
20 May 2017 - 23 May 2017

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.